2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123615
    SPD-2 1643781-40-1 98%
    SPD-2 is a photo-controlled hydrogen sulfide (H2S) donor that can generate hydrogen sulfide (H2S) upon UVA irradiation (325-385 nm). SPD-2 enables photo-controlled, site-specific H2S release in living cells.
    SPD-2
  • HY-123646
    RS 2135 133775-36-7 98%
    RS 2135 is an antiarrhythmic compound that can suppress ischemia-induced ventricular arrhythmias.
    RS 2135
  • HY-12366R
    Ubrogepant (Standard) 1374248-77-7
    Ubrogepant (Standard) is the analytical standard of Ubrogepant. This product is intended for research and analytical applications. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine.
    Ubrogepant (Standard)
  • HY-12366S
    Ubrogepant-d5 98%
    Ubrogepant-d5 (MK-1602-d5) is deuterium labeled Ubrogepant. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine.
    Ubrogepant-d5
  • HY-12376R
    BAY 41-2272 (Standard) 256376-24-6 98%
    BAY 41-2272 (Standard) is the analytical standard of BAY 41-2272. This product is intended for research and analytical applications. BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research.
    BAY 41-2272 (Standard)
  • HY-123939
    JAK1/3-IN-1 1400687-19-5 98%
    JAK1/3-IN-1 is a selective, orally active JAK1/3 inhibitor with IC50 values of 1.9 nM and 0.9 nM, respectively. JAK1/3-IN-1 significantly reduces the mean arterial blood pressure and significantly increases the heart rate in rabbits. JAK1/3-IN-1 decreases the mean arterial blood pressure in conscious telemetered rats and induces lethal cardiovascular effects.
    JAK1/3-IN-1
  • HY-12403R
    Talfirastide (Standard) 51833-78-4
    Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
    Talfirastide (Standard)
  • HY-124051
    BAY-8040 1194453-23-0 98%
    BAY-8040 is a pyrimidopyridazine derivative which has inhibitory activity against human neutrophil elastase (HNE). BAY-8040 decreases cardiac remodeling and ameliorates cardiac function in a Monocrotaline (HY-N0750)-induced rat model for pulmonary arterial hypertension. BAY-8040 is promising for research of inflammatory pathologies and cardiopulmonary pathologies.
    BAY-8040
  • HY-124208
    L-770644 173901-95-6 98%
    L-770644 is an orally active, potent and selective agonist of the human β3 adrenergic receptor (EC50 = 13 nM).
    L-770644
  • HY-124229
    PD 122860 122576-86-7 98%
    PD 122860 is a calcium channel blocker. PD 122860 also can stimulate sodium channel. PD 122860 can be used for the research of cardiovascular and cerebrovascular diseases.
    PD 122860
  • HY-124273
    C2 L-threo Ceramide (d18:1/2:0) 143615-69-4 98%
    C2 L-threo Ceramide (d18:1/2:0) (L-threo Cer(d18:1/2:0); L-threo Ceramide (d18:1/2:0)) is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It stimulates cholesterol efflux in CHO cells expressing the human ABCA1 receptor when used at a concentration of 10 μM, however, this efflux is 50% less than that stimulated by C2 ceramide. C2 L-threo Ceramide inhibits IL-4 production by 17% in EL4 T cells stimulated with phorbol 12-myristate 13-acetate when used at a concentration of 10 μM. It also induces cell cycle arrest in the G0/G1 phase and a 7-fold increase in sphingosine accumulation as well as inhibits growth of HL-60 leukemia cells.
    C2 L-threo Ceramide (d18:1/2:0)
  • HY-124458
    Morocromen 35843-07-3 98%
    Morocromen is a new 2-oco-benzopyranylcarboxamide with strong coronary activity.
    Morocromen
  • HY-124499
    RUC-1 796886-30-1 98%
    RUC-1 (Compound 1) is an inhibitor for αIIbβ3 integrin. RUC-1 inhibits fibrin deposition and platelet aggregation in hybrid hαIIb/mβ3 receptors expressing mice. RUC-1 exhibits antithrombotic effect in hαIIb/mβ3 receptor expressing mice.
    RUC-1
  • HY-124910
    BU-E-75 114667-74-2 98%
    BU-E-75 is a guanidine-type H2 receptor agonist that exhibits antagonism at postsynaptic α-adrenoceptors, which can relax the noradrenaline-precontracted vessels.
    BU-E-75
  • HY-12496R
    NS-1619 (Standard) 153587-01-0
    NS-1619 (Standard) is the analytical standard of NS-1619. This product is intended for research and analytical applications. NS-1619 is an opener of large conductance Ca2+-activated K+ (BK) channel. NS-1619 is a highly effective relaxant with an EC50 of about 10-30 μM in several smooth muscles of blood vessels and other tissues. NS1619 inhibits proliferation and induces apoptosis in A2780 ovarian cancer cells.
    NS-1619 (Standard)
  • HY-12502B
    Efonidipine hydrochloride 111011-53-1 98%
    Efonidipine (NZ-105) hydrochloride is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC50 values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride inhibits SARS-CoV-2 main protease. Efonidipine hydrochloride modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis.
    Efonidipine hydrochloride
  • HY-125086
    Leustroducsin B 145142-82-1 98%
    Leustroducsin B is a colony-stimulating factor (CSF) inducer. Leustroducsin B induces CSF production in bone marrow stromal cells.
    Leustroducsin B
  • HY-125144
    BIIB 513 265986-98-9 98%
    BIIB 513 is an inhibitor of NHE 1 that protects against myocardial ischemia. BIIB 513 inhibits acid load recovery with an IC50 of 27 nmol/L in cells expressing wild-type NHE 1 under acute acid load.
    BIIB 513
  • HY-12515R
    Nicardipine (Standard) 55985-32-5 98%
    Nicardipine (Standard) is the analytical standard of Nicardipine. This product is intended for research and analytical applications. Nicardipine (YC-93 free base) is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure.
    Nicardipine (Standard)
  • HY-12533R
    Disopyramide (Standard) 3737-09-5
    Disopyramide (Standard) is the analytical standard of Disopyramide. This product is intended for research and analytical applications. Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action.
    Disopyramide (Standard)
Cat. No. Product Name / Synonyms Application Reactivity